MedWatch

Coloplast raises EBIT margin guidance

Optimizations and lower expenses due to covid-19 mean that medtech firm Coloplast has upgraded its expected EBIT margin guidance. Simultaneously, the ostomy business is advancing compared with the same period last year.

Photo: Coloplast / PR

On Thursday, Danish medtech firm Coloplast raised its margin guidance for earnings before interest and taxation (EBIT) for the whole year. The firm reports that the upgrade is due to optimizations and lower costs brought about by the covid-19 pandemic.

Now, the medtech firm expects to have an EBIT margin of 32-33 percent, whereas the previous estimate was 31-32 percent. In terms of organic growth in revenue, the firm predicts a 7-8 percent increase after currency adjustments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs